OxyContin 5 mg prolonged release tablets
*Company:
Mundipharma Pharmaceuticals Limited - Formerly Napp LaboratoriesStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 21 March 2025
File name
PIL_Ireland-OxyContin 5, 10, 20, 40, 80mg PRT-clean.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
2. What you need to know before you take OxyContin
Warnings and precautions
Tolerance, dependence and addiction
This medicine contains oxycodone, which is an opioid. It can cause dependence and/or addiction.
This leaflet was last revised in February 2025
Updated on 21 March 2025
File name
SmPC-Ireland-OxyContin 5 mg PRT-clean.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.4 Special warnings and precautions for use
Hepatobiliary disorders
Oxycodone may cause dysfunction and spasm of the sphincter of Oddi, thus increasing the risk of biliary tract symptoms and pancreatitis. Therefore, oxycodone has to be administered with caution in patients with pancreatitis and diseases of the biliary tract.
10. Date of Revision of Text
19/03/2025
Updated on 19 March 2024
File name
OxyContin 5 mg, 10 mg, 20 mg, 40 mg, 80 mg prolonge PIL- clean.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
Updated on 19 March 2024
File name
OxyContin 5 mg prolonged release tablets - SPC- clean.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 14 December 2023
File name
OxyContin 5 mg prolonged release tablets - SPC- clean.pdf
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 14 December 2023
File name
OxyContin 5 mg, 10 mg, 20 mg, 40 mg, 80 mg prolonge PIL- clean.pdf
Reasons for updating
- Change to section 1 - what the product is used for
- Change to section 3 - how to take/use
Updated on 07 December 2023
File name
OxyContin 5 mg, 10 mg, 20 mg, 40 mg and 80 mg prolonged release tablets IE - PIL.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
Updated on 26 June 2023
File name
OxyContin 5 mg prolonged release tablets - SPC_v1.0-clean.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 26 June 2023
File name
OxyContin 5 mg, 10 mg, 20 mg, 40 mg, 80 mg prolonge PIL-clean.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 3 - how to take/use
- Change to section 3 - overdose, missed or forgotten doses
- Change to section 5 - how to store or dispose
Updated on 06 April 2023
File name
OxyContin 5 mg prolonged release tablets -SPC-clean.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
IE MAH Address Change
Updated on 06 April 2023
File name
OxyContin 5 mg, 10 mg, 20 mg, 40 mg, 80 mg-PIL-clean.pdf
Reasons for updating
- New PIL for new product
Free text change information supplied by the pharmaceutical company
IE MAH Address Change
Mundipharma Pharmaceuticals Limited - Formerly Napp Laboratories
Address:
United Drug House Magna Drive, Magna Business Park, Citywest Road, Dublin 24, IrelandMedical Information E-mail:
medicalinformation@mundipharma.ieTelephone:
Medical Information Direct Line:
+44 174 882 8867